A 6-week, open-label, randomised, multicentre, phase IIIb, parallel-group study to compare the safety and efficacy of rosuvastatin 40 mg and rosuvastatin 40 mg in combination with ezetimibe 10 mg in subjects with hypercholesterolaemia and coronary heart disease (CHD) or atherosclerosis or a CHD risk equivalent (10-year risk score of greater than 20%)

Trial Profile

A 6-week, open-label, randomised, multicentre, phase IIIb, parallel-group study to compare the safety and efficacy of rosuvastatin 40 mg and rosuvastatin 40 mg in combination with ezetimibe 10 mg in subjects with hypercholesterolaemia and coronary heart disease (CHD) or atherosclerosis or a CHD risk equivalent (10-year risk score of greater than 20%)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2006

At a glance

  • Drugs Ezetimibe; Rosuvastatin
  • Indications Cardiovascular disorders; Hypercholesterolaemia; Lipid metabolism disorders
  • Focus Therapeutic Use
  • Acronyms EXPLORER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Jul 2006 Status change
    • 28 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top